Sector
Healthcare & Life Sciences
1,129 announced healthcare & life sciences deals, most recent first, with the firms that advised on each.
Most recent
SEARCH ALL 1,129 DLA Piper advises IMVIONIX on US and Canadian commercial rights for retinal therapy 11 Nov 2026
Hogan Lovells Cadwalader advises BCM Legacy Fund in the design and formation of its fund to invest philanthropic capital in biomedical startups 11 Nov 2026
Latham & Watkins Advises Codexis on US$60 Million Term Loan Facility 11 Nov 2026
Latham & Watkins Advises ŌURA in US$625 Million Acquisition of Counsel Health 11 Nov 2026
Herbert Smith Freehills Kramer advises Meiban Group on the acquisition of Planet Innovation 10 Nov 2026
Sidley Represents Sino Biopharmaceutical in its US$7 Billion Licensing Agreement With Boehringer Ingelheim 10 Nov 2026
Hogan Lovells Cadwalader advises Rantum on growth financing for MedTech group 10 Nov 2026
Latham & Watkins Advises Unnatural Products in Sale to argenx for Up to US$1.15 Billion 10 Nov 2026
Linklaters advises Zylox-Tonbridge on acquisition of equity interest in LifeTech Scientific Corporation and new share issuance 10 Nov 2026
Hogan Lovells Cadwalader advises Neva SGR on its investment in Nouscom 9 Nov 2026
Latham & Watkins Advises on Orchestra BioMed’s US$75 Million Public Offering 9 Nov 2026
Latham & Watkins Advises Invidia Capital Management in Acquisition of Now Optics 6 Nov 2026
Latham Advises on Lyell Immunopharma’s US$80 Million Private Placement 6 Nov 2026
Latham Advises CVC, GBL Consortium, and Respighi on Groundbreaking €7.58 Billion Financing for the Voluntary Tender Offer for Recordati 6 Nov 2026
Latham & Watkins Advises Precision BioSciences on US$125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants 6 Nov 2026
Sidley Represents Laza Medical in Its US$160 Million Series B Financing Round 5 Nov 2026
Hogan Lovells Cadwalader advised Orbus International on the acquisition of MC Health 5 Nov 2026
Latham & Watkins Advises AbbVie on Global License Agreement With Nxera Pharma 5 Nov 2026
Latham & Watkins Advises Baring Asset Management on the Financing of Gilde Healthcare’s Acquisitions of BENTEC Endoscopy and Hermann Medizintechnik 5 Nov 2026
Latham Advises Carlyle and PAI Partners on Sale of Theramex to Cinven 5 Nov 2026
Linklaters advises Carlyle, PAI Partners and Theramex on the sale of Theramex to Cinven 5 Nov 2026
Sidley Represents Hanmi Pharm and Green Cross Biopharma in Licensing Agreement With BioMarin 3 Nov 2026
Latham & Watkins Advises Pelthos Therapeutics in Combination With Castle Creek Biosciences 3 Nov 2026
Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO 3 Nov 2026
Latham & Watkins Advises on Bambusa Therapeutics’ Upsized US$168.9 Million IPO 3 Nov 2026
DLA Piper advises Retension Pharmaceuticals on initial public offering 28 Oct 2026
Sidley Represents Bolt Biotherapeutics in the Acquisition of Prana Therapies and Concurrent US$120 Million Private Placement Financing 27 Oct 2026
Sidley Represents ZAP Surgical as It Secures US$36 Million in Financing 27 Oct 2026
DLA Piper advises Starpharma on majority ownership of Petalion Therapeutics 27 Oct 2026
Latham Advises on Corxel Pharmaceuticals and Amanat Acquisition Corp.’s Business Combination Agreement to Create a Publicly Listed Obesity-Focused Biopharmaceutical Company 27 Oct 2026
Latham & Watkins Advises Arcus Biosciences on US$250 Million Public Offering of Common Stock 27 Oct 2026
Linklaters advises QIAGEN on recommended voluntary all-cash public takeover offer by EQT 27 Oct 2026
Clifford Chance advises Luxinva on the voluntary public takeover offer of QIAGEN NV 22 Oct 2026
Latham & Watkins Advises Cheplapharm on Private Placement 22 Oct 2026
Herbert Smith Freehills Kramer advises DKSH on its acquisition of NewBridge Pharmaceuticals 21 Oct 2026
Sidley Represents Savillex in Its Acquisition of Entegris’ Life Sciences Fluid Management Business 21 Oct 2026
Baker McKenzie Advises Lenders on USD 800 Million Bridge Financing for Galderma’s Acquisition of ZO Skin Health 21 Oct 2026
DLA Piper advises Arlington Capital Partners and Everest Clinical Research on acquisition of Firma Clinical Research unit 21 Oct 2026
TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, have announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named TriGemX Bio, Inc. and is expected to trade on Nasdaq under the new ticker symbol TGEM. Latham & Watkins LLP represents TCGX in the transaction with a corporate team led by Houston partners Ryan Maierson and Ryan Lynch, with associates Taylor Allison, Cooper Shear, and Luisa Gomez Yokubaitis, with assistance from Zachary Mouton. Advice was also provided on tax matters by Houston partner Jared Grimley, with associates Dominick Constantino and Graham Core; on benefits matters by Los Angeles partner Michelle Carpenter, with associate Jordan Barnes; on healthcare regulatory matters by Washington, D.C. partner Nathan Beaton and counsel Nicole Liffrig Molife and Chad Jennings, with associate Margaret Rote; on funds matters by Chicago partner David Moore and New York partner Jennifer Tian;* on data cybersecurity matters by New York partner Jessica Cohen, with associates Laura Geraci and Nat Lewis; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Ryleigh Chen; on environmental matters by Los Angeles/Houston partner Joshua Marnitz, with associate Brandon Kerns; on anti-bribery and anti-money laundering matters by Washington, D.C. partner Daniel Dominguez, with associates Patricia Amselem Bensadon and Ai Ni Lim; on antitrust matters by Washington, D.C. partner Jason Cruise and Washington, D.C. counsel Ngoc Hulbig; and on economic sanctions and export controls matters by Washington, D.C. partner Eric Volkman, with associate Amulya Vadapalli. *Admitted to practice in Illinois only. 21 Oct 2026
Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton Pharmaceuticals 19 Oct 2026
DLA Piper advises Lanas on acquisition of New Zealand healthtech provider indici 19 Oct 2026
Latham & Watkins Advises Zocdoc on Acquisition of Sohar Health 19 Oct 2026
Latham & Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLsLatham & Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLs 19 Oct 2026
Latham Represents BlackRock and HPS Investment Partners in New Strategic Joint Venture With Humana to Manage CenterWell Senior Primary Care Clinics 14 Oct 2026
Latham Advises on Financing for Altaris’ Completed Acquisition of Clarivate’s Life Sciences & Healthcare Business 13 Oct 2026
Latham & Watkins Advises Partners Group on Refinancing of DELABO.group 13 Oct 2026
Latham & Watkins Advises Cheplapharm on €1.2 Billion Term Loan B 13 Oct 2026
Latham Advises on TRexBio’s US$116.7 Million Initial Public Offering 12 Oct 2026
Latham Advises H.I.G. Capital and Medisolve on Refinancing and Growth Financing 9 Oct 2026
Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE Biosciences 8 Oct 2026
Latham & Watkins Advises on Rocket Pharmaceuticals’ Growth Facility 8 Oct 2026
Latham Advises on Vaxcyte’s Concurrent Public Offerings of Common Stock, Pre-Funded Warrants, and Convertible Senior Notes 8 Oct 2026
Latham & Watkins Advises Spectrum Equity on Growth Investment in Symmetric Health Solutions 7 Oct 2026
Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITM 7 Oct 2026
DLA Piper advises IntraBio on US$2.0 billion acquisition by Shionogi 7 Oct 2026
Latham Advises Arsenal Medical in Acquisition by Terumo Neuro 6 Oct 2026
Sidley Represents Jiangsu Hengrui in Connection With US$2.6 Billion Licensing Agreement With Novo Nordisk 2 Oct 2026
Sidley Represents Pyxis Oncology in an up to US$282.6 Million Public Offering 2 Oct 2026
Latham & Watkins Advises Shareholders on Sale of SK Pharma to Arcus Infrastructure Partners 2 Oct 2026
Linklaters advises Fresenius on the full acquisition of the biopharmaceutical company mAbxience 2 Oct 2026